I
2.98
0.16 (5.67%)
| 前收盘价格 | 2.82 |
| 收盘价格 | 3.14 |
| 成交量 | 42,901 |
| 平均成交量 (3个月) | 53,275 |
| 市值 | 401,337,440 |
| 52周波幅 | |
| 利润日期 | 7 May 2025 - 12 May 2025 |
| 营业毛利率 | -176.49% |
| 营业利益率 (TTM) | -245.76% |
| 稀释每股收益 (EPS TTM) | -2.30 |
| 季度收入增长率 (YOY) | 6,798.50% |
| 总债务/股东权益 (D/E MRQ) | 7.00% |
| 流动比率 (MRQ) | 4.18 |
| 营业现金流 (OCF TTM) | -334.39 M |
| 杠杆自由现金流 (LFCF TTM) | -184.76 M |
| 资产报酬率 (ROA TTM) | -27.14% |
| 股东权益报酬率 (ROE TTM) | -51.85% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (GB) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | IOVANCE BIOTHERAPEUTICS INC IOV | - | - |
AIStockmoo 评分
-1.4
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.38 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.35% |
| 机构持股比例 | 81.25% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合